Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
28 mars 2022 06h00 HE
|
Axsome Therapeutics, Inc.
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated...
Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum
11 mars 2022 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
02 mars 2022 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
15 févr. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
11 févr. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
08 nov. 2021 07h00 HE
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021
20 oct. 2021 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million
18 oct. 2021 07h00 HE
|
Axsome Therapeutics, Inc.
$100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing...
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
16 sept. 2021 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine
14 sept. 2021 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...